ERBB2 and non-small cell lung carcinoma: Alterations in MET (3–4% of NSCLC patients), NTRK (3%), HER2 (2–4%) and RET (1–2%) genes, as well as EGFR exon 20 insertions (1–2%) are rare and mutually exclusive molecular aberrations.